<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Daly AB</submitter><funding>National Institute for Health Research (NIHR)</funding><pagination>203-208</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9873557</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>29(1)</volume><pubmed_abstract>In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol&lt;sup>-1&lt;/sup> (9.0% ± 1.4%)) underwent two 8-week periods to compare the CamAPS HX fully closed-loop app with standard insulin therapy and a masked glucose sensor (control) in random order, with a 2-week to 4-week washout between periods. The primary endpoint was proportion of time in target glucose range (3.9-10.0 mmol l&lt;sup>-1&lt;/sup>). Analysis was by intention to treat. Thirty participants were recruited between 16 December 2020 and 24 November 2021, of whom</pubmed_abstract><journal>Nature medicine</journal><pubmed_title>Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.</pubmed_title><pmcid>PMC9873557</pmcid><funding_grant_id>CL-2020-14-801</funding_grant_id><pubmed_authors>Daly AB</pubmed_authors><pubmed_authors>Hartnell S</pubmed_authors><pubmed_authors>Wilinska ME</pubmed_authors><pubmed_authors>Evans ML</pubmed_authors><pubmed_authors>Nwokolo M</pubmed_authors><pubmed_authors>Cezar A</pubmed_authors><pubmed_authors>Boughton CK</pubmed_authors><pubmed_authors>Hovorka R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.</name><description>In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. In an open-label, single-center, randomized crossover study, 26 adults with type 2 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 ± 11 years; baseline glycated hemoglobin (HbA1c), 75 ± 15 mmol mol&lt;sup>-1&lt;/sup> (9.0% ± 1.4%)) underwent two 8-week periods to compare the CamAPS HX fully closed-loop app with standard insulin therapy and a masked glucose sensor (control) in random order, with a 2-week to 4-week washout between periods. The primary endpoint was proportion of time in target glucose range (3.9-10.0 mmol l&lt;sup>-1&lt;/sup>). Analysis was by intention to treat. Thirty participants were recruited between 16 December 2020 and 24 November 2021, of whom</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-10T06:54:09.807Z</modification><creation>2025-04-07T03:18:55.131Z</creation></dates><accession>S-EPMC9873557</accession><cross_references><pubmed>36631592</pubmed><doi>10.1038/s41591-022-02144-z</doi></cross_references></HashMap>